7-French Factor: Absence Of Fidelis Lead Gives St. Jude’s Riata A Boost
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's recall of its Sprint Fidelis ICD leads will have only a small impact on overall implantable defibrillator demand, but the market leader's share will suffer as doctors seek the thinnest leads available, electrophysiologists suggested on an Oct. 29 conference call
You may also be interested in...
Medtronic ICD Sales Better Than Expected, But Some Share Goes To St. Jude
Medtronic's sales of implantable cardioverter defibrillators beat analyst expectations in the most recent fiscal quarter despite lingering fall-out from the firm's October Fidelis ICD lead recall
Medtronic ICD Sales Better Than Expected, But Some Share Goes To St. Jude
Medtronic's sales of implantable cardioverter defibrillators beat analyst expectations in the most recent fiscal quarter despite lingering fall-out from the firm's October Fidelis ICD lead recall
With ICD Leads Under Scrutiny, FDA Expects To Update Guidance In 2008
FDA plans to release new PMA guidelines for pacemaker and implantable defibrillator leads in 2008 to give manufacturers more guidance on bench testing